Filing Flows › Treace Medical Concepts (TMCI) › Q2 2026 › vs Q1 2026
Treace Medical Concepts (TMCI) Q2 2026 vs Q1 2026 (quarter over quarter)
Treace Medical Concepts's revenue fell $1.8M (-4%) from $47.2M in Q1 2026 to $45.4M in Q2 2026.
Treace Medical Concepts, Q2 2026: revenue $45.4M (-4% year over year), operating margin -33.0%, net loss $15.9M, operating cash flow −$4.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $45.4M | $47.2M | −$1.8M | -4% |
| Net loss | $15.9M | $18.0M | −$2.1M | -12% |
| Costs & expenses | $61.2M | $65.2M | −$3.9M | -6% |
| Operating costs | $60.3M | $64.4M | −$4.0M | -6% |
| Interest & other, net | $915K | $794K | $121K | +15% |
| Cost of revenue | $9.8M | $9.8M | −$22K | -0.2% |
| Research & development | $4.4M | $4.6M | −$246K | -5% |
| Sales & marketing | $30.9M | $33.8M | −$2.8M | -8% |
| General & admin | $15.2M | $16.2M | −$928K | -6% |
| Operating cash sources | $15.9M | $18.0M | −$2.1M | -12% |
| Depreciation & amortization | $1.9M | $899K | $989K | +110% |
| Share-based compensation | $6.5M | $8.0M | −$1.6M | -20% |
| Working capital & other | $2.8M | $16.3M | −$13.4M | -83% |
| Cash used in operations | $4.7M | −$7.2M | $11.9M | — |
| Net loss absorbed | $15.9M | $18.0M | −$2.1M | -12% |
Questions
How much did Treace Medical Concepts's revenue grow quarter over quarter in Q2 2026?
Treace Medical Concepts's revenue fell $1.8M (-4%) from $47.2M in Q1 2026 to $45.4M in Q2 2026.